Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Dec 26;12(12):2093-2094.
doi: 10.21037/tp-23-367. Epub 2023 Dec 22.

Late surgical intervention after childhood cancer treatment

Hideki Nakayama  1
Affiliations
Editorial

Late surgical intervention after childhood cancer treatment

Hideki Nakayama. Transl Pediatr. .
No abstract available

Keywords: Childhood cancer survivors (CCS); cumulative burden; late effects; surgical intervention.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at https://tp.amegroups.com/article/view/10.21037/tp-23-367/coif). The author has no conflicts of interest to declare.

Comment on

References

    1. Ward ZJ, Yeh JM, Bhakta N, et al. Global childhood cancer survival estimates and priority-setting: a simulation-based analysis. Lancet Oncol 2019;20:972-83. 10.1016/S1470-2045(19)30273-6 - DOI - PubMed
    1. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006;355:1572-82. 10.1056/NEJMsa060185 - DOI - PubMed
    1. Dieffenbach BV, Murphy AJ, Liu Q, et al. Cumulative burden of late, major surgical intervention in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study (CCSS) cohort. Lancet Oncol 2023;24:691-700. 10.1016/S1470-2045(23)00154-7 - DOI - PMC - PubMed
    1. Dong H, Robison LL, Leisenring WM, et al. Estimating the burden of recurrent events in the presence of competing risks: the method of mean cumulative count. Am J Epidemiol 2015;181:532-40. 10.1093/aje/kwu289 - DOI - PMC - PubMed
    1. Castellino SM, Pei Q, Parsons SK, et al. Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma. N Engl J Med 2022;387:1649-60. 10.1056/NEJMoa2206660 - DOI - PMC - PubMed